BioWednesday Webinar: Trends in Biotech M&A

Online registration is closed but if you would like to attend please contact laurabacchus@onenucleus.com

There has been no slowdown in deal activity in biotech and pharma in 2021, despite the pandemic.  Statistics suggest that deal size and volume is up on the previous year.  But we're certainly seeing some changes in the make-up of the deals.

When looking at biotech and pharma M&A, the traditional model of early-stage acquisition is evolving to later stage M&A, which is being influenced by access to funding, regulatory changes and opportunities for more stratified disease interventions with high unmet need.  With a move towards later stage deals and increasing commercialisation opportunities for biotechs, there are also different considerations for driving a deal along.

Our BioWednesday Webinar will discuss the factors driving this evolution in M&A activity and how it may play out in future, including what we are seeing as alternatives to the M&A route.

Panel
Ravi Degun, Partner, Life Sciences Commercial Access Lead, EY (Moderator)
John Baker, SVP Marketing & Josh Johnson, Head of Corporate Development, Abcam
Kevin Cox, Chairman, ValiRx
Luciana Griebel, M&A Associate, Covington & Burling LLP

Prices

One Nucleus members: Free

Non-Members: £50 + VAT

Academics: please contact alicia@onenucleus.com